HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysis
Study (n=599, with resistance testing) found 94% infections were susceptible to dolutegravir, and use as monotherapy (aOR 34.1, 95%CI 9.93-117), and in combination with lamivudine (9.21, 2.20-38.6), had higher risks of resistant infection vs combination anti-retroviral therapy.
Source:
The Lancet HIV
SPS commentary:
Dolutegravir resistance was also higher in those with potential low or low (aOR 5.23, 95%CI 1.32-20.7) or high level (13.4, 4.55-39.7) nucleoside reverse transcriptase inhibitor resistance. Authors highlight this is of concern, notably in resource-limited settings. They highlight that monitoring is important to prevent resistance at the individual and population level and ensure the long-term sustainability of anti-retroviral therapy.